Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin Plus Lenalidomide for Previously Untreated PTCL
NCT02232516Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Jun 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin and lenalidomide in peripheral T-cell lymphoma (PTCL), sponsored by Northwestern University. Primary endpoint: Objective Response Rate. Started Jun 2015; status: completed.
02
Drugs
romidepsinlenalidomide
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02232516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232516.